Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
In Focus channel feed
How a duty to spend wisely on worker benefits could loosen PBMs' grip on drug prices
5 months ago
Pharma
Law
Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future
6 months ago
AI
As 23andMe struggles, another genetic testing company bets on drug discovery
6 months ago
R&D
Discovery
Lawmakers are poking holes in pharma's favorite new way to market medicines
6 months ago
Pharma
Health Tech
A rare neurological disease is Sage’s last, best hope after failures in depression
6 months ago
R&D
Pharma
Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder
7 months ago
Startups
R&D
Biotech industry worries over potential for RFK Jr. ally as FDA pick
7 months ago
FDA+
Is there room for MASH drugs in a GLP-1 world?
7 months ago
R&D
Pharma
Bad trip: How culture conflict and a need for cash nearly broke Lykos
8 months ago
People
Recursion nears ‘moment of truth’ with first key data, kicking off 18-month flurry of readouts
9 months ago
R&D
AI
Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal
9 months ago
R&D
The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders
10 months ago
Pharma
Manufacturing
A teenager faced constant seizures. Could a drug developed just for him stop them?
11 months ago
R&D
Discovery
Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote
11 months ago
R&D
The Endpoints Slack interview: Saji Wickramasekara on where AI misses the mark — and what's next for Benchling
11 months ago
AI
Health Tech
How two academic chemists turned San Diego startup Iambic into an AI force
11 months ago
AI
BIO's new CEO takes a patriotic pivot to win back Congress, pushing industry to rethink China relationship
Last year
China
The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer
Last year
R&D
AI
After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials
Last year
China
Cell/Gene Tx
Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal
Last year
R&D
Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution
Last year
R&D
AI
With GIP, obesity research is at odds
Last year
R&D
The US could upend biopharma manufacturing. WuXi rivals have an opening
Last year
China
Manufacturing
Female investors track progress, call for more women on boards and in leadership roles
Last year
People
Financing
First page
Previous page
1
2
3
4
5
Next page
Last page